FDA Approves KedRAB [rabies immune globulin (Human)] for Post-Exposure Prophylaxis of Rabies Infection

Fort Lee, NJ/Rehovot, Israel – August 25, 2017 - Kedrion Biopharma and Kamada Ltd. (NASDAQ and TASE: KMDA), two leading human-derived protein therapeutics companies, today announced that KedRAB™ [rabies immune globulin (Human)] has received U.S....
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news